<DOC>
	<DOC>NCT02324673</DOC>
	<brief_summary>This is a Phase 1/2, open-label, trial designed to assess the pharmacokinetics, safety, tolerability, and preliminary efficacy of 3 multiple ascending doses of Cannabidiol Oral Solution in a sequential fashion. Participants will be pediatric (aged 1-17, inclusive), experiencing treatment-resistant seizures, and satisfy all inclusion/exclusion criteria.</brief_summary>
	<brief_title>Cannabidiol Oral Solution in Pediatric Subjects With Treatment- Resistant Seizure Disorders</brief_title>
	<detailed_description />
	<mesh_term>Seizures</mesh_term>
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Meets protocolspecified criteria for qualification and contraception, including treatmentresistant seizure disorder Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an informed consent form approved by the Institutional Review Board before the conduct of any study procedure In the opinion of the Investigator, the participants and parent(s)/caregiver(s) are willing and able to comply with the study procedures and visit schedules, including venipuncture, inpatient stay at the study center, dosing at the study center twice a day as needed while an outpatient), and the Followup Visits (if applicable) Subject or parent(s)/caregiver(s) have daily commitments during the study duration that would interfere with attending all study visits History or current use of dietary supplements, drugs or overthe counter medications outside protocolspecified parameters Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1. the safety or wellbeing of the participant or study staff 2. the safety or wellbeing of the participant's offspring (such as through pregnancy or breastfeeding) 3. the analysis of results</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Treatment-resistant seizures</keyword>
</DOC>